ГЕНЕТИКА GENETICS

DOI: 10.18413/2658-6533-2022-8-4-0-1

Molecular cytogenetic and cytopostgenomic analysis of the human genome

Ivan Y. Iourov^{1,2,3}, Svetlana G. Vorsanova^{1,2}, Oksana S. Kurinnaia^{1,2}, Maria A. Zelenova^{1,2}, Kirill S. Vasin^{1,2}, Irina A. Demidova^{1,2}, Alexey D. Kolotii^{1,2}, Victor S. Kravets^{1,2}, Maria E. Iuditskaia^{1,2}, Nikita S. Iakushev^{1,2}, Ilia V. Soloviev¹, Yuri B. Yurov^{1,2}

 ¹ Mental Health Research Center, 34 Kashirskoe Highway, Moscow, 115522, Russia
² Pirogov Russian National Research Medical University, 2 Taldomskaya St., Moscow, 125412, Russia
³ Russian Medical Academy of Continuous Postgraduate Education, bld. 1, 2/1 Barrikadnaya St., Moscow, 125993, Russia *Corresponding author: Ivan Y. Iourov (ivan.iourov@gmail.com)*

Abstract

Background: Despite the achievements of human genomics, comprehensive genome analysis, including acquiring the knowledge about intercellular and interindividual variations at (sub)chromosomal/cytogenomic level, remains a difficult task. This basically results from a lack of heuristic algorithms for uncovering (cyto)genomic and/or somatic genome variations and the functional outcomes. However, current developments in molecular cytogenetics and "cytopostgenomics" may offer a solution of the problem. The aim of the study: To present a heuristic algorithm for molecular cytogenetic and cytopostgenomic analysis of the human genome to uncover mechanisms of genetic (brain/neurodevelopmental) diseases. Materials and methods: Data on cytogenetic and (cyto)genomic variations (chromosome abnormalities, chromosome/genome instability, copy number variation (CNV) etc.) addressed by original molecular cytogenetic techniques and processed by original bioinformatic (cytopostgenomic) methods were used to develop the algorithm. Karyotyping was performed in 8556 individuals. FISH analysis was applied when required (cases of somatic mosaicism/chromosome instability). Molecular karyotyping by SNP-array was performed in 600 (~7%) cases. Results: Using our long-term experience of studying chromosomal and genomic variations/instability in neurodevelopmental disorders as well as original developments in (cyto)genomic data processing, we managed to present a heuristic algorithm for molecular cytogenetic and cytopostgenomic analysis of the human genome to uncover mechanisms for brain diseases. Estimated efficiency of the algorithm was established to achieve 84%. Analyzing the dynamics of applying cytogenetic and cytogenomic techniques throughout ~35 years of our diagnostic research we found that the diagnostic efficiency had been increasing from ~7% (exclusive diagnosis by karyotyping) to more than 80% (molecular cytogenetic and cytopostgenomic analysis). Conclusion: Here, we propose a heuristic algorithm for molecular cytogenetic and cytopostgenomic analysis of the human genome to

(cc) BY

uncover mechanisms for genetic diseases. The efficiency and ability to uncover mechanisms of chromosome instability allows us to conclude that the algorithm may be highly competitive for basic and diagnostic genomic/cyto(post)genomic research.

Keywords: chromosome; chromosomal instability; genome; genome instability; molecular cytogenetics; human disease; brain disease; bioinformatics; neurodevelopmental disorders; cytogenomics

For citation: Iourov IY, Vorsanova SG, Kurinnaia OS, et al. Molecular cytogenetic and cytopostgenomic analysis of the human genome. Research Results in Biomedicine. 2022;8(4):412-423. DOI: 10.18413/2658-6533-2022-8-4-0-1

Introduction. Molecular cytogenetic and cytogenomic analyses have become an important part of diagnostic and basic research focused on uncovering genetic mechanisms of a disease [1-4]. Brilliant discoveries of novel genetic mechanisms for brain disorders [5, 6, 7] obliged to reevaluate diagnostic workflows and approaches to identification of genomic variations associated with a disease. Nonetheless, there are still numerous problems associated with cytogenomic diagnosis roughly referred to genome mapping, difficulties of interpretation of genome variations (i.e. copy number variation or CNV), and understanding the meaning of somatic genome variations [3, 8, 9]. On the other hand, systems analysis applied to cytogenomic data seems to be able to solve these problems [10]. Additionally, molecular cytogenetic and genetic techniques (e.g. fluorescence in situ hybridization or FISH and genome scanning methods) have a number of limitations, i.e. analysis of specific genome loci (FISH), lack of reproducible interpretation and moderate cell scoring potential (genome scanning methods) [11], which are, however, may be also overcome by the application of bioinformatic or "cytopostgenomic" methods [12]. Furthermore, these methods are required for complementing the knowledge about genome variations [13], i.e. genome behavior at the interindividual [14] and at intercellular levels [15]. Accordingly, it is highly likely that combinations of molecular cytogenetic, cytogenomic and bioinformatic techniques may underlie approaches to uncovering disease mechanisms [16-19].

To succeed in unraveling genomic mechanisms of genetic diseases, genome data are to be processed for estimating functional outcomes of changes in genetic material [16, 20]. More precisely, these data are to be used for uncovering molecular and cellular pathways to a disease [20]. In the molecular cytogenetic/cytogenomic context, these studies have to address somatic chromosomal mosaicism and chromosome/genome instability in addition to disease pathways [15, 20-25]. Furthermore, cytogenomic variations are generally more complex than those affecting single genes [26, 27]. In total, there is a need to address all the variations detectable in an individual genome (variome) with respect to mosaicism and genomic/chromosomal instability for understanding causes and consequences of cytogenomic variations [28]. This becomes even more significant, taking into account the ability of chromosome instability or genome chaos to produce pathological conditions (e.g. cancer and neurodegeneration) through the lifespan [25, 29-32]. Finally, the systems biology methodology (bioinformatics or systems genomics) [33, 34], applied to cytogenomic and cytogenetic data should be efficient for uncovering genetic/genomic mechanisms of a variety of clinical conditions [10, 28, 35] leading to a possibility of treating diseases associated with chromosome imbalances, which are generally considered as incurable [36]. In conclusion, we suggest that combining all the aforementioned methods and may provide a heuristic algorithm for unraveling cytogenomic mechanisms for genetic brain diseases.

The aim of the study. Here, using our previous developments in molecular cytogenetics and cytopostgenonics and analysis of data on karyotyping of 8556 individuals with neurodevelopmental disorders and congenital malformations, we have presented a heuristic algorithm for unraveling (cyto)genomic mechanisms for genetic diseases.

Materials and methods. Karyotyping data, acquired as described previously [37, 38],

was obtained during a long-term study (from 1985 to present) of 8556 individuals with neurodevelopmental disorders (intellectual disability, autism, epilepsy, behavioral abnormalities) and congenital malformations. FISH was applied in cases of somatic mosaicism and/or chromosome instability according to previous protocols of hybridization and detection [37-39]. FISH data were acquired from Vorsanova et al. 2021 and 2022 [37, 38]. Molecular karyotyping by SNP array was performed in 600 cases from the karyotyped cohort. The protocol of SNP array was repeatedly described previously [40-43]. Bioinformatic analyses were carried out by an original methodology, which included systems genome (variome) analysis, data fusion, "CNV laundering" and pathway-based prioritization of genomic variations. All these techniques were recently described in detail elsewhere [16, 20, 28, 44, 45].

Results and discussion. Previously, we proposed that karyotyping (cytogenetic analysis) is the initial step of genomic data analysis, which is required for understanding the variability and behavior of an individual genome [17]. More precisely, it was recommended to obtain two data sets: cytogenetic and genomic (cytogenomic). This proposal was lately supported by Breman and Stankiewicz, who noted that karyotyping is to be applied at the start of diagnostic genome research [46]. Figure 1 schematically demonstrates this idea.




Fig. 1. Schematic depiction of the algorithm for investigating the molecular and cellular mechanisms of diseases mediated by CIN. To succeed, one has to follow green arrows or, in other words, to analyze chromosome instability by karyotyping and FISH (analysis of larger amounts of cells) instead of the commonly accepted workflow including only cytogenetic karyotyping and molecular karyotyping; bioinformatics is mandatory for uncovering disease mechanisms. (Copyright © Vorsanova et al. 2019 [17]; an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited).

Taking into account the efficiency of combining FISH and SNP array (Fig. 2) [36-40], we propose to use these techniques for analyzing cytogenomic variations. The idea is even more apposite for cases of chromosomal instability and mosaicism as well as aneuploidy/polyploidy cases, inasmuch as it gives an opportunity to uncover the molecular and cellular causes of the instability in addition to detection intercellular variations caused by genome chaos (i.e. description of the nature of chromosomal instability) [6, 8, 10, 17, 25, 28, 30, 31].




Fig. 2. An example of molecular cytogenetic analysis depicted by a study of a female with non-mosaic monosomy X; (A) FISH with a DXZ1 DNA probe (chromosome X, one green signal) and D1Z1 DNA probe (chromosomes 1, two red signals); (B) SNP-array results demonstrating non-mosaic X chromosome loss (regular monosomy X). (Copyright © Vorsanova et al. 2021 [37]; an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited).

Focusing on karyotyping data obtained from studying 8556 individuals with neurodevelopmental disorders and congenital malformations, allowed us to select a very specific group of individuals (n=600; $\sim7\%$), who require molecular karyotyping and extended bioinformatic analysis of genome data. SNP array was selected as a technique of choice, inasmuch as it allows detecting chromosomal imbalances and CNVs at the highest resolution [40-43] and segmental uniparental disomies within imprinted loci [40, 47]. Thus, a heuristic algorithm for comprehensive genome analysis for medical genetics does require both karyotyping (classical cytogenetics) and molecular karyotyping by SNP array. Since FISH allows single-cell monitoring of genomic/chromosomal variations, it is, thereby, required for cases of mosaicism and chromosome/genome instability

Despite the studies reporting significantly increased diagnostic efficiency rates resulted from the application of array genome scanning techniques, understanding the mechanisms of the diseases and unraveling the cellular and molecular pathways requires a bioinformatic addition to the analytic workflows [16, 28, 32, 36, 44, 48]. Bioinformatic approaches to analyze data obtained by new sequencing technologies including panel versions were suggested to be an alternative [9, 11, 48, 49]. However, the alternative remains questionable, since these approaches do not provide intrinsic data on diseases mechanisms/pathways, inasmuch as genomic mechanisms are much more sophisticated than previously envisaged [20, 28, 50]. Moreover, these mechanisms become even more complicated when somatic genomic mosaicism and chromosome/genome instability are taken into account [3, 7, 15, 25, 51, 52]. Considering the data that applications of the simplest digital tools appreciably increase the yield of molecular cytogenetic genome analysis [1, 17, 53-55], sophisticated bioinformatic techniques are likely to provide the highest efficiency in diagnostic/research cytogenomic analyses [7, 16, 28, 44, 45]. Here, we have added to the algorithm all of our original developments in genomic data processing, which include OMICs data input/processing (variome

analysis, data collection, CNV prioritization) [3, 10, 12, 16, 28, 44], CNV laundering [45], pathway-based analyses of variome for candidate process or CNV prioritization [16, 20, 28, 36, 44] (Fig. 3).

Combining the aforementioned cytogenetic, molecular cytogenetic and cytogenomic or cytopostgenomic approaches seems to result in uncovering mechanisms of a disease associated with a set of genomic variations (disease variome), clinical outcomes of which are mediated by chromosomal/genomic instability and/or molecular and cellular pathways (candidate processes). In this light, it is to note again that morbid conditions associated with chromosomal/genomic instability range from infertility to pathogenic aging, from early onset neurodevelopmental disorders to late onset neurodegenerative and neuropsychiatric diseases, from immunodeficiency to cancer [1-3, 6, 7, 15, 22-25, 29-31, 51, 52]. Finally, the described heuristic algorithm in its final form may be depicted, as follows (Fig. 4).

Our long-term experience (from 1985 to the present) [1, 17, 37, 38] allowed us to highlight the dynamics of efficiency changes in dependence of introducing molecular cytogenetic and postgenomic techniques (Fig. 5). Initially, karyotyping uncovers ~7% of genomic variations (chromosomal abnormalities) in neurodevelopmental disorders. The introduction of in situ hybridization (ISH) gave instantly 12% of detection of chromosomal abnormalities. Further introduction and developments of FISH (e.g. increasing DNA probe numbers, multicolor FISH [39], analysis of chromosomal instability and mosaicism) increased the efficiency to 34% (~3 times increase). Metaphase or classical comparative genomic hybridization (CGH) in combination with FISH and karvotyping allowed to detect chromosomal variations in 40% of individuals from the neurodevelopmental cohort. Substitution of CGH by array CGH (CGH on chips; laser detection) increased the efficiency to 48%. SNP array with the highest resolution of molecular karyotyping (up to 1 kbp), used instead of array CGH, gave an unprecedented efficiency in detection of chromosomal abnormalities and CNV (including intragenic CNV) estimated as 61-64%

(depending on protocol/variation size filter). Finally, in silico molecular cytogenetic analysis using bioinformatic, postgenomic/cytopostgenomic or pathway-based classification made a breakthrough in efficiency of genomic variation detection, which achieved 80-84%. In this context, we would like to mention that these efficiency rates were achievable by an extremely thorough selection (clinical and cytogenetic selection) of cases to be addressed by genome scanning, FISH and cytopostgenomic methods.





Fig. 3. Bioinformatic part of the algorithm (see text for more details).



Bioinformatic analysis for fusion of data sets (non-genomic data, genomic variations, chromosome/genome instability, somatic mosaicism and pathways altered by genomic variations)

Fig. 4. Schematic representation of the algorithm for molecular cytogenetic and cytopostgenomic analysis of the human genome, which is based on data collection (non-genomic, classical and molecular karyotypic, whole-genome etc.), analysis of somatic mosaicism and chromosome instability by FISH and karyotyping, postgenomic pathway based classification of variome and candidate processes; to finalize the algorithm, all these data sets are then processed by bioinformatic analysis for the fusion.




Fig. 5. Dynamics of diagnostic/detective efficiency depending on the introduction of molecular cytogenetic and postgenomic techniques in neurodevelopmental disorders from 1985 to the present.

Conclusion. Our communication describes a heuristic algorithm for molecular cytogenetic and cytopostgenomic analysis of the human genome, which may be successfully used to uncover mechanisms for genetic diseases (especially, brain genetic disorders). The algorithm is also applicable for identification of causes and consequences of somatic chromosomal mosaicism and chromosome/genome instability, which are common mechanisms for a wide spectrum of human morbid conditions. The rise of detection rates produced by introducing molecular cytogenetic and cytopostgenomic techniques was a basis for developing the algorithm, the efficiency of which was high enough to conclude that it is highly competitive for research and diagnostic purposes during forthcoming genomic or cyto(post)genomic studies.

Financial support

Our study is partially supported by the Government Assignment of the Russian Ministry of Health, Assignment no. AAAA-A18– 118051590122-7 and by the Government Assignment of the Russian Ministry of Science and Higher Education, Assignment no. AAAA-A19–119040490101-6.

Conflict of interests

The authors have no conflict of interest to declare.

References

1. Vorsanova SG, Yurov YB, Soloviev IV, et al. Molecular cytogenetic diagnosis and somatic genome variations. Current Genomics. 2010;11(6):440-446. DOI: https://doi.org/10.2174/138920210793176010

2. Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. Annual Reviews of Medicine. 2010;61:437-455. DOI: https://doi.org/10.1146/annurev-med-100708-204735.

3. Iourov IY, Vorsanova SG, Yurov YB. Single cell genomics of the brain: focus on neuronal diversity and neuropsychiatric diseases. Current Genomics. 2012;13(6):477-488. DOI: https://doi.org/10.2174/138920212802510439

4. Liehr T. Molecular cytogenetics in the era of chromosomics and cytogenomic approaches.

Frontiers in Genetics. 2021;12:720507. DOI: https://doi.org/10.3389/fgene.2021.720507

5. Wain LV, Armour JA, Tobin MD. Genomic copy number variation, human health, and disease. The Lancet. 2009;374(9686):340-350. DOI: https://doi.org/10.1016/S0140-6736(09)60249-X

6. Potter H, Chial HJ, Caneus J, et al. Chromosome instability and mosaic aneuploidy in neurodegenerative and neurodevelopmental disorders. Frontiers in Genetics. 2019;10:1092. DOI: https://doi.org/10.3389/fgene.2019.01092

7. Iourov IY, Vorsanova SG, Kurinnaia OS, et al. Causes and consequences of genome instability in psychiatric and neurodegenerative diseases. Molecular Biology. 2021;55(1):37-46. Russian. DOI:

https://doi.org/10.31857/S0026898421010158

8. Liehr T. About classical molecular genetics, cytogenetic and molecular cytogenetic data not considered by Genome Reference Consortium and thus not included in genome browsers like UCSC, Ensembl or NCBI. Molecular Cytogenetics. 2021;14(1):20. DOI: https://doi.org/10.1186/s13039-021-00540-7

9. Royer-Bertrand B, Cisarova K, Niel-Butschi F, et al. CNV detection from exome sequencing data in routine diagnostics of rare genetic disorders: opportunities and limitations. Genes. 2021;12(9):1427. DOI:

https://doi.org/10.3390/genes12091427

10. Iourov IY, Vorsanova SG, Yurov YB. Systems Cytogenomics: are we ready yet? Current Genomics. 2021;22(2):75-78. DOI: https://doi.org/10.2174/138920292266621021911 2419

11. Andriani GA, Maggi E, Piqué D, et al. A direct comparison of interphase FISH versus low-coverage single cell sequencing to detect aneuploidy reveals respective strengths and weaknesses. Scientific Reports. 2019;9(1):10508. DOI: https://doi.org/10.1038/s41598-019-46606-w

12. Iourov IY. Cytopostgenomics: what is it and how does it work? Current Genomics. 2019;20(2):77-78. DOI: https://doi.org/10.2174/138920292002190422120 524

13. Hu Q, Maurais EG, Ly P. Cellular and genomic approaches for exploring structural chromosomal rearrangements. Chromosome Research. 2020;28(1):19-30. DOI: https://doi.org/10.1007/s10577-020-09626-1

14. Spielmann M, Lupiáñez DG, Mundlos S. Structural variation in the 3D genome. Nature Reviews Genetics. 2018;19(7):453-467. DOI: https://doi.org/10.1038/s41576-018-0007-0

15. Iourov IY, Vorsanova SG, Yurov YB, et al. Ontogenetic and pathogenetic views on somatic chromosomal mosaicism. Genes. 2019;10(5):379. DOI:

https://doi.org/10.3390/genes10050379

16. Iourov IY, Vorsanova SG, Yurov YB. In silico molecular cytogenetics: a bioinformatic approach to prioritization of candidate genes and copy number variations for basic and clinical genome research. Molecular Cytogenetics. 2014;7(1):98. DOI:

https://doi.org/10.1186/s13039-014-0098-z

17. Vorsanova SG, Yurov YB, Soloviev IV, et al. FISH-based analysis of mosaic aneuploidy and chromosome instability for investigating molecular and cellular mechanisms of disease. OBM Genetics. 2019;3(1):068. DOI: https://doi.org/10.21926/obm.genet.1901068

18. Liu Q, Karolak JA, Grochowski CM, et al. Parental somatic mosaicism for CNV deletions - A need for more sensitive and precise detection methods in clinical diagnostics settings. Genomics. 2020;112(5):2937-2941. DOI: https://doi.org/10.1016/j.ygeno.2020.05.003

19. Liehr T. False-positives and false-negatives in non-invasive prenatal testing (NIPT): what can we learn from a meta-analyses on > 750,000 tests? Molecular Cytogenetics. 2022;15(1):36. DOI: https://doi.org/10.1186/s13039-022-00612-2

20. Iourov IY, Vorsanova SG, Yurov YB. Pathway-based classification of genetic diseases. Molecular Cytogenetics. 2019;12:4. DOI: https://doi.org/10.1186/s13039-019-0418-4

21. Heng HH, Horne SD, Chaudhry S, et al. A postgenomic perspective on molecular cytogenetics. Current Genomics. 2018;19(3):227-239. DOI:

https://doi.org/10.2174/138920291866617071714 5716

22. Rodin RE, Walsh CA. Somatic mutation in pediatric neurological diseases. Pediatric Neurology. 2018;87:20-22. DOI: https://doi.org/10.1016/j.pediatrneurol.2018.08.008

23. Graham EJ, Vermeulen M, Vardarajan B, et al. Somatic mosaicism of sex chromosomes in the blood and brain. Brain Research. 2019;1721:146345. DOI: https://doi.org/10.1016/j.brainres.2019.146345

24. Jourdon A, Fasching L, Scuderi S, et al. The role of somatic mosaicism in brain disease. Current Opinion in Genetics and Development. 2020;65:84-90.

https://doi.org/10.1016/j.gde.2020.05.002

25. Iourov IY, Yurov YB, Vorsanova SG, et al. Chromosome instability, aging and brain diseases. Cells. 2021;10(5):1256. DOI: https://doi.org/10.3390/cells10051256

26. Mostovoy Y, Yilmaz F, Chow SK, et al. Genomic regions associated with microdeletion/microduplication syndromes exhibit extreme diversity of structural variation. Genetics. 2021;217(2):iyaa038. DOI: https://doi.org/10.1093/genetics/iyaa038

27. Burssed B, Zamariolli M, Bellucco FT, et al. Mechanisms of structural chromosomal rearrangement formation. Molecular Cytogenetics. 2022;15(1):23. DOI: https://doi.org/10.1186/s13039-022-00600-6

28. Iourov IY, Vorsanova SG, Yurov YB. The variome concept: focus on CNVariome. Molecular Cytogenetics. 2019;12:52. DOI: https://doi.org/10.1186/s13039-019-0467-8

29. Dai X, Guo X. Decoding and rejuvenating human ageing genomes: Lessons from mosaic chromosomal alterations. Ageing Research Reviews. 2021;68:101342. DOI: https://doi.org/10.1016/j.arr.2021.101342

30. Heng J, Heng HH. Genome chaos, information creation, and cancer emergence: searching for new frameworks on the 50th anniversary of the "war on cancer". Genes. 2021;13(1):101. DOI: https://doi.org/10.3390/genes13010101

31. Ye JC, Horne S, Zhang JZ, et al. Therapy induced genome chaos: a novel mechanism of rapid cancer drug resistance. Frontiers in Cell and Developmental Biology. 2021;9:676344. DOI: https://doi.org/10.3389/fcell.2021.676344

32. Jiang X-F, Xiong L, Bai L, et al. Structure and dynamics of human complication-disease network. Chaos, Solitons and Fractals. 2022;164:112633. DOI: https://doi.org/10.1016/j.chaos.2022.112633

33. Ideker T, Hood L. A blueprint for systems biology. Clinical Chemistry. 2019;65(2):342-

344. DOI: https://doi.org/10.1373/clinchem.2018.291062

34. García-Hernández JL, Corchete LA, Marcos-Alcalde Í, et al. Pathogenic convergence of CNVs in genes functionally associated to a severe neuromotor developmental delay syndrome. Human Genomics. 2021;15(1):11. DOI: https://doi.org/10.1186/s40246-021-00309-4

35. Peña-Chilet M, Esteban-Medina M, Falco MM, et al. Using mechanistic models for the

DOI:

clinical interpretation of complex genomic variation. Scientific Reports. 2019;9(1):18937. DOI: https://doi.org/10.1038/s41598-019-55454-7

36. Iourov IY, Vorsanova SG, Voinova VY, et al. 3p22.1p21.31 microdeletion identifies CCK as Asperger syndrome candidate gene and shows the way for therapeutic strategies in chromosome imbalances. Molecular Cytogenetics. 2015;8:82. DOI: https://doi.org/10.1186/s13039-015-0185-9

37. Vorsanova SG, Kolotii AD, Kurinnaia OS, et al. Turner's syndrome mosaicism in girls with neurodevelopmental disorders: a cohort study and hypothesis. Molecular Cytogenetics. 2021;14(1):9. DOI:

https://doi.org/10.1186/s13039-021-00529-2

38. Vorsanova SG, Demidova IA, Kolotii AD, et al. Klinefelter syndrome mosaicism in boys with neurodevelopmental disorders: a cohort study and an extension of the hypothesis. Molecular Cytogenetics. 2022;15(1):8. DOI: https://doi.org/10.1186/s13039-022-00588-z

39. Iourov IY, Liehr T, Vorsanova SG, et al. Interphase chromosome-specific multicolor banding (ICS-MCB): a new tool for analysis of interphase chromosomes in their integrity. Biomolecular Engineering. 2007;24(4):415-417. DOI: https://doi.org/10.1016/j.bioeng.2007.05.003

40. Iourov IY, Vorsanova SG, Korostelev SA, et al. Long contiguous stretches of homozy-gosity spanning shortly the imprinted loci are associated with intellectual disability, autism and/or epilepsy. Molecular Cytogenetics. 2015;8:77. DOI: https://doi.org/10.1186/s13039-015-0199-3

41. da Silva FB, Machado-Neto JA, Bertini VHLL, et al. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. Journal of Clinical Pathology. 2017;70(5):435-442. DOI: https://doi.org/10.1136/jclinpath-2016-204023

42. Papenhausen PR, Kelly CA, Harris S, et al. Clinical significance and mechanisms associated with segmental UPD. Molecular Cytogenetics. 2021;14(1):38. DOI:

https://doi.org/10.1186/s13039-021-00555-0

43. Perovic D, Damnjanovic T, Jekic B, et al. Chromosomal microarray in postnatal diagnosis of congenital anomalies and neurodevelopmental disorders in Serbian patients. Journal of Clinical Laboratory Analysis. 2022;36(6):e24441. DOI: https://doi.org/10.1002/jcla.24441 44. Yurov YB, Vorsanova SG, Iourov IY. Network-Based Classification of Molecular Cytogenetic Data. Current Bioinformatics. 2017;12(1):27-33. DOI: https://doi.org/10.2174/157489361166616060616 5119

45. Zelenova MA, Yurov YB, Vorsanova SG, et al. Laundering CNV data for candidate process prioritization in brain disorders. Molecular Cytogenetics. 2019;12:54. DOI: https://doi.org/10.1186/s13039-019-0468-7

46. Breman A, Stankiewicz P. Karyotyping as the first genomic approach. Genomics of Rare Diseases: Academic Press; 2021:17-34. DOI: https://doi.org/10.1016/B978-0-12-820140-4.00002-8

47. Chaves TF, Oliveira LF, Ocampos M, et al. Long contiguous stretches of homozygosity detected by chromosomal microarrays (CMA) in patients with neurodevelopmental disorders in the South of Brazil. BMC Medical Genomics. 2019;12(1):50. DOI: https://doi.org/10.1186/s12020.010.0406.5

https://doi.org/10.1186/s12920-019-0496-5

48. Peedicayil J. Identification of biomarkers in neuropsychiatric disorders based on systems biology and epigenetics. Frontiers in Genetics. 2019;10:985. DOI: https://doi.org/10.3389/fgene.2019.00985

49. Singh AK, Olsen MF, Lavik LAS, et al. Detecting copy number variation in next generation sequencing data from diagnostic gene panels. BMC Medical Genomics. 2021;14(1):214. DOI: https://doi.org/10.1186/s12920-021-01059-x

50. Diab NS, Barish S, Dong W, et al. Molecular genetics and complex inheritance of congenital heart disease. Genes. 2021;12(7):1020. DOI: https://doi.org/10.3390/genes12071020

51. Ye Z, McQuillan L, Poduri A, et al. Somatic mutation: The hidden genetics of brain malformations and focal epilepsies. Epilepsy Research. 2019;155:106161. DOI: https://doi.org/10.1016/j.eplepsyres.2019.106161

52. Costantino I, Nicodemus J, Chun J. Genomic mosaicism formed by somatic variation in the aging and diseased brain. Genes. 2021;12(7):1071. DOI:

https://doi.org/10.3390/genes12071071

53. Peycheva V, Kamenarova K, Ivanova N, et al. Chromosomal microarray analysis of Bulgarian patients with epilepsy and intellectual disability. Gene. 2018;667:45-55. DOI: https://doi.org/10.1016/j.gene.2018.05.015

54. Lee CL, Lee CH, Chuang CK, et al. Array-CGH increased the diagnostic rate of developmental delay or intellectual disability in Taiwan. Pediatrics and Neonatology. 2019;60(4):453-460. DOI https://doi.org/10.1016/j.pedneo.2018.11.006

55. Chehbani F, Tomaiuolo P, Picinelli C, et al. Yield of array-CGH analysis in Tunisian children with autism spectrum disorder. Molecular genetics & genomic medicine. 2022;10(8):e1939. DOI: https://doi.org/10.1002/mgg3.1939

Received 30 July 2022 Revised 11 September 2022 Accepted 14 September 2022

Information about the authors

Ivan Y. Iourov, Doct. Sci. (Biology), Professor of the Russian Academy of Sciences, Head of the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenetics, Mental Health Research Center; Head of the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University; Professor at the Department of Medical Genetics, Russian Medical Academy of Continuing Professional Education, Moscow, Russia, E-mail: ORCID: ivan.iourov@gmail.com, https://orcid.org/0000-0002-4134-8367.

Svetlana G. Vorsanova, Doct. Sci. (Biology), Professor, Honored Scientist of Russia, Academician of the Russian Academy of Natural Sciences, Head of the Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University; Chief Researcher at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenomics (before 2021), Mental Health Re-Russia, Center. Moscow, search E-mail: svorsanova@mail.ru, **ORCID:** https://orcid.org/0000-0002-4869-5361.

Oksana S. Kurinnaia, Cand. Sci. (Biology), Senior Researcher at the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University; Senior Researcher at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenetics, Mental Health Research Center, Moscow, Russia, E-mail: kurinnaiaos@mail.ru, ORCID: https://orcid.org/0000-0002-7087-3929. Maria A. Zelenova, Cand. Sci. (Biology), Senior Researcher at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenetics, Mental Health Research Center; Researcher at the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University, Moscow, Russia, Email: maria_zelenova@yahoo.com, ORCID: https://orcid.org/0000-0001-7458-5396.

Kirill S. Vasin, Cand. Sci. (Medicine), Researcher at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenetics, Mental Health Research Center; Researcher at the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University, Moscow, Russia, E-mail: vasinks@rambler.ru, ORCID: https://orcid.org/0000-0002-2799-3706.

Irina A. Demidova, Cand. Sci. (Biology), Leading Researcher at the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University; Leading Researcher at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenomics, Mental Health Research Center, Moscow, Russia, E-mail: demidovaia@yandex.ru, ORCID: https://orcid.org/0000-0002-8143-7604.

Alexey D. Kolotii, Cand. Sci. (Biology), Senior Researcher at the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University; Senior Researcher at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenomics, Mental Health Research Center, Moscow, Russia, E-mail: kolotiyad@yandex.ru, ORCID: https://orcid.org/0000-0002-7672-588X.

Victor S. Kravets, Cand. Sci. (Biology), Researcher at the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University; Senior Researcher at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenomics, Mental Health Research Center, Moscow, Russia, E-mail: victorskravets@gmail.com, ORCID: https://orcid.org/0000-0002-6345-3993.

Maria M. Iuditskaia, Assistant at the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University; Assistant at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenomics, Mental Health Research Center, Moscow, Russia, E-mail: myudickaya@mail.ru, OR-CID: https://orcid.org/0000-0003-4443-7039.

Nikita S. Iakushev, Assistant at the Professor Vorsanova Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University; Assistant at the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenomics, Mental Health Research Center, Moscow, Russia, E-mail: nikita.yakushev.1999@gmail.com, ORCID: https://orcid.org/0000-0002-6053-7550.

Ilia V. Soloviev, Cand. Sci. (Medicine), Researcher at the Laboratory of Cytogenetics and Genomics of Mental diseases, Mental Health Research Center, Moscow, Russia, E-mail: svorsanova@mail.ru, ORCID: https://orcid.org/0000-0002-5982-8983.

Yuri B. Yurov, Doct. Sci. (Biology), Professor, Honored Scientist of Russia, Academician of the Russian Academy of Natural Sciences, Head of the Professor Yurov Laboratory of Molecular Genetics and Brain Cytogenetics (before 2017), Mental Health Research Center; Chief Researcher at the Laboratory of Molecular Cytogenetics of Neuropsychiatric Diseases (before 2017), Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University, Moscow, Russia, E-mail: ivan.iourov@gmail.com, ORCID: https://orcid.org/0000-0002-4134-8367.